Pricefx Reimagines Pricing Software with Groundbreaking Product Enhancements
2.12.2020 17:30:00 EET | Business Wire | Press release
Pricefx, the global leader in cloud-native pricing software, today announced the new face of its pricing platform. Unity UI is a sleek, dynamic new look for all of Pricefx’s industry-leading pricing modules. The company has also launched PriceOptimizer AI, a next-generation price optimization solution powered by transparent and predictive machine learning and multi-agent AI. Finally, Pricefx introduced new Accelerators, pre-defined solution building blocks that quickly and easily incorporate best practice functionality. With these new enhancements, Pricefx is now more streamlined, powerful and agile than ever before. Now, businesses using Pricefx can get more done and price more effectively with fewer clicks.
“2020 revealed the critical importance of pricing in a digital-first world and Pricefx invested heavily in developing and refining our pricing platform to ensure that businesses around the world can successfully use our software to build a path to growth,” said Marcin Cichon, CEO and co-founder at Pricefx. “From the new, modern user interface to the groundbreaking AI-powered price optimizer and the pre-built Accelerators, Pricefx is delivering impressive product functionality to the market. We continue to live our commitment to providing customers fast, flexible and friendly solutions that help them achieve revenue and profit goals faster than ever.”
Unity UI
Pricefx platform modules are now unified in a modern, sleek UI that streamlines the user experience by ensuring that everything is at the user’s fingertips. Pricing workflows are simplified with a single application that works across multiple platforms and devices. To reduce management overhead, Pricefx can be customized for different users and easily incorporated into third-party CRM or ERP applications.
PriceOptimizer AI
With PriceOptimizer AI, Pricefx is introducing the industry’s first price optimization engine powered by multi-agent AI, a powerful approach that uses multiple interacting intelligent agents to arrive at the best outcome. With this breakthrough, PriceOptimizer AI can simulate multiple business objectives at once and simultaneously optimize the entire price waterfall at every level of granularity, from list prices to rebates. This means Pricefx customers can align competing business rules, priorities and constraints, such as price increases, competition or margin targets, resulting in far more realistic pricing strategy.
Additionally, users can evaluate multiple best outcomes even when the model is over constrained. They can model price elasticity to see precisely which constraints are impacting the optimized list price, discount or rebate. Then, users can easily change models, simulate the impact of changes and adjust constraints during run-time. This faster, more flexible approach to price optimization achieves massive time savings, with updates to thousands of prices and sales conditions in just minutes.
In combination with “clear box” segmentation and predictive ML algorithms, PriceOptimizer AI delivers transparent and intuitive price optimization, enabling pricing leaders to confidentially arm sales with deal guidance they can stand behind.
“Although the term ‘artificial intelligence’ can conjure up an image of robots taking over the world, the best use of AI is eliminating robotic work from a process so that people are free to use their experience and judgment to make better decisions more consistently,” observed Robert Kugel, Senior Vice President and Research Director at Ventana Research. “Making decisions about optimal pricing within a set of prioritized objectives, business rules and constraints is an ideal use case for AI provided that the system is fully transparent so individuals can trust the outcome. Increasingly, companies are finding that intelligent pricing enables them to improve both revenues and margins with a sustainable competitive advantage.”
Accelerators
With Pricefx Accelerators, customers can use pre-defined solution building blocks to deploy new modules and functionality even faster, while reducing overall effort and cost. By adding industry best practice functionality, Pricefx customers and partners can quickly and easily configure solutions out of the box, while still retaining customization capabilities. Not only do Accelerators reduce implementation effort and time to value, they also lower the total cost of ownership for the Pricefx platform by making it easier to support and enhance functionality.
Specifically, the new Sales Insights Accelerator delivers rapid insights into profitability, margin leakage and profit outliers. Customers can see how margin and revenue change over time based on factors like customer acquisition and variances in price, as well as quickly find and address outliers by analyzing your best and worst performing customers and products.
Availability
Unity UI, PriceOptimizer AI and Accelerators are generally available now as part of the Vesper release.
About Pricefx
Established in 2011 in Germany, Pricefx is the global leader in SaaS pricing software, offering a comprehensive suite of solutions that are fast to implement, flexible to configure and customize, and friendly to learn and use. Pricefx delivers a complete price optimization and management platform based on native cloud architecture, providing industry leading time to value and total cost of ownership advantages to customers. Their innovative solution works for both B2B and B2C enterprises of any size, in any industry, in any part of the world. Pricefx’s business model is entirely based on the satisfaction and loyalty of its customers. Today, Pricefx delivers Passion for Pricing to more than 100 customers in more than 37 countries worldwide. For more information, please visit www.pricefx.com .
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201202005174/en/
Contact information
Media Contact:
Cathy Summers
Summers PR
cathy@summers-pr.com
+1 (415) 483-0480
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 09:00:00 EET | Press release
Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers across Europe to bring advanced proton treatment to their patients. “With both FDA clearance and CE Marking now in hand, the MEVION S250-FIT is
Bureau Veritas: Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 08:30:00 EET | Press release
Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2024, › Free Cash Flow of EUR 824.2 million, up 3.9% organically and up 2.6% at constant currency, and cash conversion of 107%2, › Adjusted net
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 08:00:00 EET | Press release
Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat in a mouse model in Sandhoff disease, a form of GM2 gangliosidosis with no approved treatments—alongside healthy control subjects. The research assessed how the drug’s exposure relates to its effects in the brain, demonstrating a significant increase in both survival (22%; 26 days) and assessments of movement and behavior at 16 weeks versus un
Galderma Announces Triple Approval of New State-of-the-Art Restylane ® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA® lidocaine range of Restylane products in multiple facial indications including the cheeks, nose, chin, jawline, tear troughs, nasolabial folds, marionette lines, as well as in the hands.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224651688/en/ The syringe features a next-generation ergonomic design that enhances precision and control; includes an optimized syringe-needle connection with the new Terumo K-Pack Enhance™ needle; and offers a premium color-coded packaging and syringe design to support easy range navigation for practitioners.4-7, 9,10 It sets a new standard in Injectable Aesthetic devices and demonstrates Galderma’s unwavering commitment to driving innovation to meet the needs of both practitioners and patients. “Developing this new syringe
Verdict Expected Soon in Klarna’s $8.3 Billion Antitrust Lawsuit Against Google24.2.2026 20:09:00 EET | Press release
Klarna Group plc (NYSE: KLAR) announces that the Patent and Market Court of Sweden (Patent- och marknadsdomstolen) is expected to deliver its verdict on April 15, 2026 in the antitrust damages proceedings brought by Klarna’s subsidiary PriceRunner International AB against Google LLC and Google Ireland Limited. The trial, which ran from October 20 to December 19, 2025, concerned PriceRunner’s claim for approximately $8.3 billion in damages — the largest civil damages claim ever filed in a Swedish court. The Case The claim arises from Google’s abuse of dominance in online comparison shopping, as established by the European Commission in a binding 2017 decision and upheld without reservation by the Court of Justice of the European Union in September 2024. PriceRunner alleges that Google systematically demoted competing price comparison services in its search results while favouring its own Google Shopping product, causing sustained and quantifiable commercial damage to PriceRunner over mo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
